Opportunity Information: Apply for RFA HD 14 027
Apply for RFA HD 14 027
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Safety and Effectiveness of Triple Antiretroviral Drug Strategies for Prevention of Mother to Child HIV Transmission (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Feb 11, 2013 and posted on Feb 11, 2013.
- Applicants must submit their applications by Aug 30, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $5,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Special district governments County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Public housing authorities/Indian housing authorities For profit organizations other than small businesses Small businesses City or township governments Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Safety and Effectiveness of Triple Antiretroviral Drug Strategies for Prevention of Mother to Child HIV Transmission (R01) funding opportunity (RFA-HD-14-027) was a discretionary NIH research grant program issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Its central goal was to support studies that test, in real-world conditions, how well triple antiretroviral (ARV) drug strategies work to prevent mother-to-child transmission of HIV in resource-constrained settings, while also carefully tracking safety for both mothers and infants. Rather than focusing only on whether these regimens can work under ideal circumstances, the FOA emphasized implementation in settings where health systems may face constraints such as limited staffing, limited laboratory capacity, inconsistent follow-up, and challenges around medication supply and adherence.
The FOA specifically called for research evaluating the safety and effectiveness of two closely related programmatic approaches to maternal ARV use during pregnancy and breastfeeding. One approach is to provide triple ARV prophylaxis during pregnancy and breastfeeding and then discontinue ARVs after breastfeeding ends for women who do not otherwise need treatment for their own health; the World Health Organization has referred to this as “Option B.” The other approach is to start lifelong antiretroviral therapy (ART) in all pregnant women regardless of clinical stage or immune status (often referred to as “Option B+”). In practical terms, the announcement aimed to generate evidence that could help countries and programs decide how to roll out these strategies at scale, understanding not just transmission outcomes but also maternal and infant health outcomes, feasibility, and potential unintended consequences of starting or stopping therapy around the breastfeeding period.
From a funding and administrative standpoint, this was an NIH R01 mechanism, meaning it was intended for substantial, hypothesis-driven research projects with strong study designs and clearly defined outcomes. The estimated total funding level listed for the opportunity was $5,000,000. There was no cost sharing or matching requirement, which is typical for NIH research grants and lowers barriers for applicants who might otherwise struggle to provide non-federal matching funds.
The opportunity was posted on February 11, 2013, with an original and current application due date of August 30, 2013. The archive date was September 30, 2013, indicating it is no longer open but remains accessible for historical reference and program transparency. The CFDA number associated with the program was 93.865 (Child Health and Human Development Extramural Research), aligning it with NICHD’s broader mission to improve maternal and child health through research.
Eligibility for this FOA was broad and included many types of U.S. domestic organizations, such as state, county, city/township, and special district governments; public and state-controlled institutions of higher education; private institutions of higher education; independent school districts; and a range of nonprofit and for-profit entities (including small businesses). Importantly for HIV implementation research, the FOA also allowed foreign organizations and foreign institutions to apply, and it permitted foreign components of U.S. organizations as defined by NIH policy. It explicitly listed eligibility for organizations that often play key roles in global health and community-based HIV work, including faith-based and community-based organizations, Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and Asian American Native American Pacific Islander serving institutions (AANAPISIs), among others. This broad eligibility framework signaled an intent to encourage applications from groups with strong ties to affected communities and from institutions operating directly in high-burden settings.
Overall, the FOA was designed to strengthen the evidence base behind triple ARV strategies for preventing mother-to-child HIV transmission when implemented at scale in low-resource environments. By targeting both safety and effectiveness and by focusing on programmatic approaches like Option B and Option B+, the announcement sought to support research that could directly inform policy, clinical guidelines, and national HIV program decisions, particularly around how long women should remain on ART initiated during pregnancy and how to manage ART through the breastfeeding period in ways that protect infants while also safeguarding maternal health.
The full announcement was hosted through the NIH grants guide (link provided in the source data). For access problems, the NIH Office of Extramural Research (OER) webmaster contact was listed (FBOWebmaster@OD.NIH.GOV), reflecting the standard NIH support channel for technical issues related to funding opportunity postings.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This was an NIH research grant funding opportunity announcement (FOA) titled "The Safety and Effectiveness of Triple Antiretroviral Drug Strategies for Prevention of Mother to Child HIV Transmission (R01)", with FOA number RFA-HD-14-027. It was issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
What was the main goal of the FOA?
The central goal was to support studies that test, under real-world conditions, how well triple antiretroviral (ARV) drug strategies prevent mother-to-child transmission (MTCT) of HIV in resource-constrained settings, while also carefully tracking safety for both mothers and infants.
What makes the research focus "real-world" rather than ideal conditions?
The FOA emphasized implementation in settings where health systems may face constraints such as limited staffing, limited laboratory capacity, inconsistent follow-up, and challenges related to medication supply and adherence.
Which ARV program approaches did the FOA specifically call for evaluating?
The FOA specifically called for research evaluating the safety and effectiveness of two closely related approaches to maternal ARV use during pregnancy and breastfeeding:
- Option B: Provide triple ARV prophylaxis during pregnancy and breastfeeding, then discontinue ARVs after breastfeeding ends for women who do not otherwise need treatment for their own health.
- Option B+: Start lifelong antiretroviral therapy (ART) in all pregnant women regardless of clinical stage or immune status.
Why were Option B and Option B+ important to study?
The FOA aimed to generate evidence to help countries and programs decide how to roll out these strategies at scale, considering not only transmission outcomes but also maternal and infant health outcomes, feasibility, and potential unintended consequences of starting or stopping therapy around the breastfeeding period.
What types of outcomes did the FOA emphasize beyond HIV transmission?
In addition to prevention of mother-to-child transmission, the FOA emphasized tracking safety for mothers and infants, evaluating maternal and infant health outcomes, assessing feasibility in constrained health systems, and identifying potential unintended consequences linked to initiating or discontinuing ART around breastfeeding.
What grant mechanism was used for this opportunity?
The FOA used the NIH R01 mechanism, which is intended for substantial, hypothesis-driven research projects with strong study designs and clearly defined outcomes.
How much total funding was associated with this FOA?
The estimated total funding level listed for the opportunity was $5,000,000.
Was cost sharing or matching required?
No. The FOA stated there was no cost sharing or matching requirement, which is typical for NIH research grants.
When was the opportunity posted?
The FOA was posted on February 11, 2013.
What was the application due date?
The original and current application due date listed was August 30, 2013.
Is this FOA still open for applications?
No. The archive date was September 30, 2013, which indicates the FOA is no longer open and is available for historical reference and transparency.
What CFDA number was associated with this program?
The FOA was associated with CFDA 93.865, listed as Child Health and Human Development Extramural Research, aligning it with NICHD's research mission related to maternal and child health.
Who was the issuing NIH institute?
The issuing institute was the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
What types of U.S. organizations were eligible to apply?
Eligibility was broad and included many types of U.S. domestic organizations, including:
- State governments
- County governments
- City or township governments
- Special district governments
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Independent school districts
- Nonprofit organizations
- For-profit organizations (including small businesses)
Were foreign organizations eligible to apply?
Yes. The FOA allowed foreign organizations and foreign institutions to apply, and it also permitted foreign components of U.S. organizations as defined by NIH policy.
Did the FOA encourage applications from community-based or faith-based organizations?
Yes. The FOA explicitly listed eligibility for organizations that often play key roles in global health and community-based HIV work, including faith-based and community-based organizations.
Which minority-serving institutions were explicitly included as eligible?
The FOA explicitly listed eligibility for a range of minority-serving institutions, including:
- Historically Black Colleges and Universities (HBCUs)
- Hispanic-serving institutions
- Tribally Controlled Colleges and Universities
- Alaska Native and Native Hawaiian serving institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)
What kinds of settings were the studies intended to address?
The studies were intended to address resource-constrained settings, particularly those where health systems may face operational constraints that affect implementation and follow-up.
What was the overall purpose of generating evidence under this FOA?
The FOA was designed to strengthen the evidence base behind triple ARV strategies for preventing mother-to-child HIV transmission when implemented at scale, with findings intended to help inform policy, clinical guidelines, and national HIV program decisions, especially regarding how long women should remain on ART initiated during pregnancy and how to manage ART through breastfeeding.
Where was the full announcement hosted?
The full announcement was hosted through the NIH grants guide (a link was provided in the source data).
Who was listed as a contact for access or technical problems with the posting?
For access problems, the NIH Office of Extramural Research (OER) webmaster contact listed was FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: High Impact Neuroscience Research Resource Grants (R24)
Previous opportunity: The Influence of the Microbiome on Preterm Labor and Delivery (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HD 14 027
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HD 14 027) also looked into and applied for these:
| Funding Opportunity |
|---|
| Specialized Cooperative Centers Program in Reproduction and Infertility Research (U54) Apply for RFA HD 14 017 Funding Number: RFA HD 14 017 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Orthotics for Pediatric Populations (SBIR) (R43) Apply for RFA HD 14 029 Funding Number: RFA HD 14 029 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $225,000 |
| Orthotics for Healthy Development (STTR) (R41) Apply for RFA HD 14 028 Funding Number: RFA HD 14 028 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Mucosal Environment and HIV Prevention (MEHP) (R01) Apply for RFA AI 13 012 Funding Number: RFA AI 13 012 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $400,000 |
| Male Contraceptive Development Program (U01) Apply for RFA HD 14 023 Funding Number: RFA HD 14 023 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Methods Development for Obtaining Comprehensive Genomic Information from Human Specimens that are Easy to Collect and Store (R43/R44) Apply for PAR 13 203 Funding Number: PAR 13 203 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Dual Purpose with Dual Benefit Research in Biomedicine and Agriculture Using Agriculturally Important Domestic Animal Species (R01) Apply for PAR 13 204 Funding Number: PAR 13 204 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Biophysical and Biomechanical Aspects of Embryonic Development (R21) Apply for PAR 13 206 Funding Number: PAR 13 206 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Biophysical and Biomechanical Aspects of Embryonic Development (R01) Apply for PAR 13 207 Funding Number: PAR 13 207 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $500,000 |
| Outcome Measures for Use in Treatment Trials for Individuals with Intellectual and Developmental Disabilities (R01) Apply for PAR 13 213 Funding Number: PAR 13 213 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01) Apply for PAR 13 195 Funding Number: PAR 13 195 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $499,999 |
| Pediatric Critical Care and Trauma Scientist Development Program (K12) Apply for RFA HD 14 019 Funding Number: RFA HD 14 019 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $720,037 |
| In vivo Methods for Assessing Placental Development and Function (SBIR) (R43/R44) Apply for RFA HD 14 005 Funding Number: RFA HD 14 005 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| In vivo Methods for Assessing Placental Development and Function (R41/R42) Apply for RFA HD 14 004 Funding Number: RFA HD 14 004 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| NICHD Program Project Grant (P01) Apply for PAR 13 257 Funding Number: PAR 13 257 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (U54) Apply for RFA AR 13 021 Funding Number: RFA AR 13 021 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Developmental Mechanisms of Human Structural Birth Defects (P01) Apply for PAR 13 285 Funding Number: PAR 13 285 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Biomarkers Bridging Pediatric and Adult Therapeutics (R03) Apply for PAR 13 299 Funding Number: PAR 13 299 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| Biomarkers Bridging Pediatric and Adult Therapeutics (R21) Apply for PAR 13 295 Funding Number: PAR 13 295 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Biomarkers Bridging Pediatric and Adult Therapeutics (R01) Apply for PAR 13 296 Funding Number: PAR 13 296 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HD 14 027", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.